One in eight Americans over the age of 12 are taking antidepressants, and two-thirds of them do not respond to their initial treatment. VistaGen Therapeutics is developing a desperately-needed treatment option. The company's CEO Shawn Singh caught up with Cheddar about AV-101 and its potential implications for the industry.